Are you Dr. Pagel?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 49 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1221 Madison St
Suite 1020
Seattle, WA 98104Phone+1 206-386-2267Fax+1 206-215-1655
Summary
- Dr. John Pagel, MD is an oncologist in Seattle, Washington. He is currently licensed to practice medicine in Washington and California. He is affiliated with Swedish First Hill Campus, UW Medicine/University of Washington Medical Center, and Seattle Children's Hospital.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 1999 - 2002
University of California (San Francisco)Residency, Internal Medicine, 1996 - 1999
Boston University School of MedicineClass of 1996
Certifications & Licensure
CA State Medical License 1998 - Present
WA State Medical License 1999 - 2026
Clinical Trials
- Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome Start of enrollment: 2003 May 01
- Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission Start of enrollment: 2007 Feb 01
- Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome Start of enrollment: 2007 Oct 05
- Join now to see all
Publications & Presentations
PubMed
- Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambuci...Jeff P Sharman, Miklos Egyed, Wojciech Jurczak, Alan Skarbnik, John M Pagel
Leukemia. 2024-12-03 - Association between class III obesity and overall survival in previously untreated younger patients with acute myeloid leukemia enrolled on SWOG S1203.Michelle Y Zhang, Megan Othus, Kerry McMillen, Harry P Erba, Guillermo Garcia-Manero
Leukemia. 2024-07-01 - 1 citationsTargeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors.Johnnie J Orozco, Phuong T Vo, Ted A Gooley, Robyn L Haaf, Sally J Lundberg
Clinical Cancer Research. 2024-01-17
Press Mentions
Actinium Pharmaceuticals Applauds CancerCare® for Launching the First Ever Acute Myeloid Leukemia Awareness MonthJune 2nd, 2016
Grant Support
- Bone Marrow Transplantation For Hematologic Malignancies Using Novel RadioimmunotNational Cancer Institute2010–2012
- Radioimmunotherapy For LeukemiaNational Cancer Institute2011
- Radioimmunotherapy Of CD20+ Lymphomas &Cd45+LeukemiasNational Cancer Institute2004–2008
- Radiolabeled Bc8, Flu, TBI And PBSC Transplant For Elderly AML Or MDS PatientsNational Center For Research Resources2006–2007
- Radiolabeled Bc8, Fludarabine, TBI Followed By PBSC Transplant For Advanced AMLNational Center For Research Resources2006
- Radiolabeled Bc8 (Anti-Cd45) Antibody Treatment For Acute Myeloid LeukemiaNational Center For Research Resources2005
- Phase I Study: Elderly Patients With Myeloid Leukemia Or Myelodysplastic SyndromNational Center For Research Resources2005
- A Feasibility Trial Combining Radiolabeled Bc8 Antibody With FludarabineNational Center For Research Resources2005
- Phase II Study For Acute Myelogenous Leukemia In FirstNational Center For Research Resources2004
Professional Memberships
- Member
